000			01838cam a2200337 a 4500
003			EG-GiCUC
005			20250223031026.0
008			140817s2013 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.12.02.M.Sc.2013.As.H
100	0		_aAsmaa Mostafa Abdelaal Mohamed
245	1	0	_aHuman Interleukin 12 gene as a biomarker for response to interferon treatment in hepatitis C virus patients / _cAsmaa Mostafa Abdelaal Mohamed ; Supervised Samar Samir Youssef , Amr Saad Mohamed
246	1	5	_aجين الإنترلوكين 12 فى الانسان كدليل حيوى للإستجابة لعلاج الإنترفيرون فى المرضى المصابين بفيروس الإلتهاب الكبدى الوبائى سى
260			_aCairo : _bAsmaa Mostafa Abdelaal Mohamed , _c2013
300			_a135 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Science - Department of Biochemistry
520			_aIntroduction: Hepatitis C virus (HCV) infection"The silent killer" is a global blood-borne disease that affects almost 3% of the worlds population with the highest prevalence in Egypt (15%). the standard therapy, PEG-IFN and ribavirin , is effective in only 60% of Egyptian patients; moreover it is costly, prolonged and have severe side effects, so prediction of response is essential to reduce burden of unfavorable treatment
530			_aIssued also as CD
653		4	_aHepatitis C virus (HCV)
653		4	_aIL 12 gene
653		4	_aResponse to PEG-IFN therapy
700	0		_aAmr Saad Mohamed , _eSupervisor
700	0		_aSamar Samir Youssef , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAml _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c46895 _d46895